BioMarin Pharmaceutical Inc. today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback